ACAT · XBRL financial data
NP Life Sciences Health Industry Group financial statements, every fiscal year
The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ACAT's year ends in late December)
| In thousands of dollars | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|
| Revenue from contracts with customers | 43 | 15 | 35 | 102 | 165 |
| General and administrative | 152 | 146 | 101 | 121 | 165 |
| Operating income (loss) | (109) | (131) | (66) | (19) | (1) |
| Interest expense | — | — | — | 0 | 1 |
| Income tax expense (benefit) | — | — | — | — | 2 |
| Net income (loss) | (109) | (131) | (66) | (19) | (3) |
| Earnings per share, basic USD per share | — | — | — | 0.00 | 0.00 |
| Earnings per share, diluted USD per share | — | — | — | 0.00 | 0.00 |
| Weighted average shares, basic thousands of shares | — | — | 42,960 | 42,960 | 42,960 |
| Weighted average shares, diluted thousands of shares | — | — | — | 42,960 | 42,960 |
Balance sheet
CSVFiscal years (ACAT's year ends in late December)
| In thousands of dollars | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 243 | 119 | 28 | 122 | 71 |
| Total assets | 250 | 119 | 38 | 128 | 77 |
| Accounts payable | 1 | — | — | 6 | 6 |
| Accrued liabilities | 14 | 15 | 0 | 3 | 25 |
| Total current liabilities | — | — | — | 108 | 38 |
| Total liabilities | 15 | 15 | 0 | 108 | 60 |
| Accumulated deficit | (130) | (261) | (326) | (345) | (348) |
| Total stockholders' equity | 235 | 104 | 38 | 19 | — |
| Total liabilities and equity | 250 | 119 | 38 | 128 | 77 |
| Common shares outstanding (cover page) thousands of shares | 42,960 | 42,960 | 42,960 | 42,960 | 42,960 |
Cash flows
CSVFiscal years (ACAT's year ends in late December)
| In thousands of dollars | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|
| Net income (loss) | (109) | (131) | (66) | (19) | (3) |
| Net cash from operating activities | (113) | (124) | (91) | 94 | (74) |
| Net cash from investing activities | (9) | — | — | — | — |
| Proceeds from issuing equity | 364 | — | — | — | — |
| Proceeds from long-term debt | — | — | — | — | 22 |
| Net cash from financing activities | 364 | — | — | — | 22 |
| Net change in cash | 243 | 124 | (91) | 94 | (51) |
Compare with peers
SIC 8200 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 8200 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| NP Life Sciences Health Industry Group | 71 | 10* | (14)* | 43.0M | 5.1 quarters | 10-KDec 31, 2023 |
| ATA Creativity Global | 85,236 | year only | year only | 63.9M | — | 20-FDec 31, 2025 |
| Afya | 1,125,381 | year only | year only | not reported | — | 20-FDec 31, 2025 |
| Ambow Education Holding | 4,469 | 2,393 | 1,067* | not reported | — | 10-QJun 30, 2026 |
| American Public Education | 146,548 | 171,731 | 12,137* | 18.3M | — | 10-QJun 30, 2026 |
| Aspen Group | 1,604 | 15,574 | (1,830)* | 25.5M | 0.9 quarters | 10-QJan 31, 2023 |
| Covista | 222,223 | 511,534 | 114,038 | 33.3M | — | 10-QSep 30, 2026 |
| Bright Scholar Education Holdings | 493,377 | year only | year only | 118.7M | — | 20-FAug 31, 2024 |
| Boxlight | 4,302 | 25,918 | (2,423)* | 667,393 | 1.8 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.